The effects of a myasthenic serum on the acetylcholine receptors of C2 myotubes. I. Immunological distinction between the two toxin-binding sites of the receptor

We have examined the effect of a serum from a patient with myasthenia gravis on the binding of alpha-bungarotoxin (alpha-BuTx) to the acetylcholine receptors (AChRs) of a mouse muscle cell line, C2. After a 2-hr incubation, antibodies in the serum reduced toxin binding to C2 myotubes to a maximal extent of approximately 50%. The degradation of surface AChRs could account for the loss of only 5% of sites during the incubation; the remainder, therefore, must have been lost by blockage of binding. To investigate whether the antibodies blocked specifically one of the two toxin-binding sites that each AChR possesses, we used an analysis based on that of Sine, S. W., and P. Taylor, [1981) J. Biol. Chem. 255: 10144-10156). Although the two sites could not be distinguished by their rates of binding of alpha-BuTx, d-tubocurarine (dTC) inhibition of the initial rate of toxin binding revealed that the sites had affinities for dTC that differed by approximately 30-fold. Incubation with the myasthenic antibodies reduced the number of high affinity dTC sites, without affecting those of low affinity. We conclude that the two toxin-binding sites of the AChR are immunologically distinct.

The effects of a myasthenic serum on the acetylcholine receptors of C2 myotubes. II. Functional inactivation of the receptor

We have investigated the effect of antibodies from a myasthenic serum on the physiological properties of acetylcholine receptors (AChRs) in myotubes of a mouse muscle cell line, C2. The antibodies in this serum blocked the binding of 125I-alpha-bungarotoxin to the myotubes to an extent of about 50%. The antibodies also inhibited the increase in 22Na influx caused by carbamylcholine (CARB). At a concentration of antibody that blocked about 50% of toxin binding, greater than 80% of the AChR-mediated 22Na influx was blocked. The apparent KD for CARB, estimated from the dose-response curve for 22Na influx, was unaffected. The effect of the antibodies was further examined by patch-clamp recording. In greater than 30% of the patches from antibody-treated cells, no channel activity in response to acetylcholine was seen; in contrast, every patch from control cells showed activity. The channels that were seen after antibody treatment were indistinguishable from those seen in normal cells, both in their single-channel conductance and in the kinetic constants used to describe channel opening and closing. We conclude that the antibodies in this serum inhibit the functional response of AChRs in C2 myotubes to acetylcholine and do so by inactivating individual receptors.